Federal Inventions Available for License
Taken from the recent online editions of the Federal Register
Department of Health & Human Services (20 inventions)
Department of the Navy (38 inventions)
Department of Health and Human Services
ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
Structure Determination of Materials Using Electron Microscopy
Sriram Subramaniam (NCI)
[DHHS Reference No. E-187-01/0 filed 23 Apr 2001]
Licensing Contact: Dale Berkley; 301/496-7735 ext. 223; e-mail: berkleyd@od.nih.gov
The invention is a method for automating the acquisition of electron microscopic images from a desktop computer interface to provide for data collection by any user from any location. Automated low-dose image acquisition procedures are used to record high-resolution images on either film or CCD, at desired defocus values, and under conditions that satisfy user-specified limits for drift rates of the specimen stage. In a fully automated procedure of the invention, the determination of regions suitable for imaging are carried out automatically using spiral search algorithms. All steps subsequent to insertion of the specimen in the microscope can be carried out on a remote personal computer connected to the microscope computer via the Internet.
Lever Coil Sensor for Respiratory and Cardiac Motion
Kenneth W. Fishbein (NIA)
DHHS Reference No. E-134-01/0 filed 30 Mar 2001]
Licensing Contact: Dale Berkley; 301/496-7735 ext. 223; e-mail: berkleyd@od.nih.gov
The invention is a device that generates a signal for synchronizing an MRI scanner with a subject's respiratory and cardiac motion to prevent blurring of the image during the scan. This device uses a small electromagnetic pickup coil to simultaneously sense respiratory and cardiac motion and provide a synchronization signal.The invention uses a mechanical linkage to keep the pickup coil far from the center of the scanner's radio frequency and gradient coils, thereby eliminating artifacts in the sensor signal and magnetic resonance images caused by mutual inductance. The signal generated by this device is proportional to chest velocity rather than chest height and is, therefore, free of any offset voltages, permitting peak location with a simple threshold detector, and is large in amplitude even for small animal subjects. The invention operates without the need for any electrical leads inside the magnet and thus eliminates any burn hazards for the patient. This device provides an inexpensive alternative to commercially available bellows sensors and fiber optically coupled units. Unlike competing sensors, this invention can be inserted, removed, or adjusted without removing the subject from the magnet and can operate with the subject in a prone or supine position. This invention has applications in both animal and human imaging studies.
Vessel Surface Reconstruction With a Tubular Deformable Model
Yim et al. (CC)
[DHHS Reference No. E-239-01/0 filed 15 Feb 2001]
Licensing Contact: Dale Berkley; 301/496-7735 ext. 223; e-mail: berkleyd@od.nih.gov
The invention is a method for modeling a carotid or renal artery to measure stenosis from 3D angiographic data that may otherwise exhibit limited image resolution and contrast. The method reconstructs vessel surfaces from 3D angiographic data using a deformable model that employs a tubular coordinate system. Vertex merging is incorporated into the coordinate system to maintain even vertex spacing and to avoid problems of self-intersection of the surface. This method produces reconstructed surfaces that have a realistic smooth appearance and accurately represent vessel shape. The method allows for an objective evaluation of vessel shape and may improve the precision of shape measurements from 3D angiography.This abstract revises one published in the Federal Register on Tuesday, May 20, 2001 (66 FR 29154) as DHHS Reference No. E-202-00/1.
Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney Jr. (NIAID)
[DHHS Reference No. E-120-01/0 filed 22 May 2001]
Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail: salatac@od.nih.gov
Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. This invention relates to dengue virus mutations that may contribute to the development of improved dengue vaccines. Site directed and random mutagenesis techniques were used to introduce mutations into the dengue virus genome and to assemble a collection of useful mutations for incorporation in recombinant live attenuated dengue virus vaccines. The resulting mutant viruses were screened for several valuable phenotypes, including temperature sensitivity in Vero cells or human liver cells, host cell restriction in mosquito cells or human liver cells, host cell adaptation for improved replication in Vero cells, and attenuation in mice or in mosquitoes. The genetic basis for each observed phenotype was determined by direct sequence analysis of the genome of the mutant virus. Mutations identified through these sequencing efforts have been further evaluated by re-introduction of the identified mutations, singly, or in combination, into recombinant dengue virus and characterization of the resulting recombinant virus for phenotypes. In this manner, a menu of attenuating and growth promoting mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccine candidates. The mutations promoting growth in Vero cells have usefulness for the production of live or inactivated dengue virus vaccines.
Subgenomic Replicons of the Flavivirus Dengue
Xiaowu Pang (CBER/FDA)
[DHHS Reference No. E-228-00/0 filed 09 Mar 2001]
Licensing Contact: Carol Salata; 301/496-7735 ext. 232; e-mail: salatac@od.nih.gov
Dengue virus, with its four serotypes Den-1 to Den-4, is the most important member of the Flavivirus genus with respect to infection of human producing diseases that range from flu-like symptoms of dengue fever (DF) to severe or fatal illness of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue outbreaks continue to be a major public health problem in densely populated areas of the tropical and subtropical regions, where mosquito vectors are abundant. This invention relates to the construction of all four types of dengue subgenomic replicons (chromosome and plasmid which contain genetic information necessary for their own replication) containing large deletions in the structural region (C-preM-E) of the genome. Immunization using these replicons should be effective in eliciting not only a humoral-mediated immune response but also a cell-mediated immune response. These replicons should be safer than a live attenuated vaccine because they cannot cause disease in the host and they should be better than subunit vaccines because they can replicate in the host.
ADDRESSES: Licensing information, and copies of the U.S. patent applications listed below, may be obtained by writing to Thomas E. O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton Rd., Atlanta, GA 30333, telephone (404) 498-0170, facsimile (404) 498-0095, and e-mail tto@cdc.gov. Please note that a signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
Apparatus for Applying Chemicals to Rodents
This invention comprises a method of controlling Lyme disease by preventing the maturation of deer ticks on white-footed mice by exposing the mice to insecticides as they enter food-baited boxes. Other tick- and flea-borne diseases can also be controlled by this
method.
Inventors: Gary O. Maupin et al. U.S. Patent Application SN: 09/595,034 (CDC Ref. #: I-031-00).
Control of Arthropod Vectors of Parasitic Diseases
This invention comprises a method of controlling Lyme disease by preventing the maturation of deer ticks on white-footed mice by exposing the mice to insecticides as they enter food-baited boxes. Other tick- and flea-borne diseases can also be controlled by this method.
Inventors: Gary O. Maupin et al. U.S. Patent Application SN: 09/595,035 (CDC Ref. #: I-032-00).
Control of Arthropods in Rodents
This invention comprises a method of controlling Lyme disease by preventing the maturation of deer ticks on white-footed mice by exposing the mice to insecticides as they enter food-baited boxes. Other tick- and flea-borne diseases can also be controlled by this method.
Inventors: Gary O. Maupin et al. U.S. Patent Application SN: 09/595,177 (CDC Ref. #: I-041-00).
Method for Monitoring Local Reaction Associated With Injections
A simple and inexpensive method to give patients a guideline for determining the severity of an adverse reaction that may occur at the site of injection. Patients can be instructed to notify health care providers if an inflammatory response spreads beyond a measured distance from the location of injection.
Inventor: Laurie Kamimoto, U.S. Patent Application SN: 60/238,691 (CDC Ref. #: I-036-00).
Auscultory Training System
This invention provides for the precise reproduction of recorded sounds. Under ordinary conditions, a sound signal is distorted by the amplifier, speakers, and the surroundings. This invention modifies the signal delivered to the speaker in such a way as to precisely reproduce the signal as it was originally recorded. The graphical user-interface allows for the easy selection and playback of individual components of a larger sound recording. This invention could have applications as a diagnostic screening tool, as a telemedicine tool, and as a teaching tool to instruct the user on the various body sounds, such as lung, bowel, or heart sounds.
Inventors: Walter McKinney et al. U.S. Patent Application SN: To be assigned, filed 4.30.2001. (CDC Ref. #: I-037-00).
Peptide Vaccines Against Group A Streptococci
The invention is a vaccine comprised of three synthetic peptides of 20-25 amino acids in length from different M proteins. The synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies in mice. The vaccine may have the potential to eliminate over 85% of Group A Streptococci infections and reduce by 85% the nasopharyngeal reservoir of Group A Streptococci in the United States.
Inventors: Bernard Beall et al. U.S. Patent Application SN: To be assigned, filed 5.18.2001. (CDC Ref. #: I-039-00)
DNA Synthesis by the Cooperative Action of DNA Polymerase and Nuclease
Confirmation of a diagnosis of an infectious agent usually depends upon the detection of the causative agent or its signature effect on the immune system. Nucleic acid detection methods offer the greatest sensitivity but depend upon specific hybridization of a primer or a probe, thus they can only be used to detect nucleic acids. This invention comprises a novel method of diagnostic detection which retains the sensitivity of nucleic acid based amplification methods while allowing detection of non-nucleic acid targets such as antibodies, surface proteins, or other antigenic components. Thus, no specific sequence information need be known about the potential target.
Inventors: Yuri Khudyakov, U.S. Patent Application SN: (CDC Ref. #: I-043-00)
BACTID--Microcomputer Programs and Databases for the Identification of Enterobacteriaceae, Vibrionaceae, and Other Microorganisms
BACTID consists of a software program coupled with a database whereby the user enters a description of an unknown microorganism which the software compares to the database for the purpose of identification of the unknown. This program allows regional diagnostic labs to access national databases which provide for greater sensitivity and specificity in identification of unknowns without the need to transfer samples to larger labs.
Inventor: John J. Farmer, U.S. Patent Application SN: Application yet to be filed. (CDC Ref. #: I-045-00)
ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Peter A. Soukas, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7056 ext. 268; fax: 301/402-0220; e-mail: soukasp@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: These inventions relate to therapeutics for Herpes Simplex Virus (HSV), a major public health threat. Results of a recent, nationally representative study show that genital herpes infection, caused by HSV-2, is common in the United States. Nationwide, 45 million people ages 12 and older, or one out of five of the total adolescent and adult population, is infected with HSV-2. Once infected with HSV, people remain infected for life. The inventors' research has shown that these compounds are significantly more potent than current therapeutics for HSV. Development of these inventions would provide a significant benefit to the public health in the form of potentially lower cost therapeutics based on the potency of the compounds.
Conformationally Locked Nucleoside Analogues
Victor E. Marquez, Juan B. Rodriguez, Marc C. Nicklaus, Joseph J. Barchi, Jr., Maqbool A. Siddiqui (NCI)
U.S. Patent 5,629,454 issued 13 May 1997; U.S. Patent 5,869,666 issued 9 Feb 1999; PCT/US94/10794 (issued as European Patent Number 0720604 and Australian Patent Number 677441)and
Conformationally Locked Nucleoside Analogs as Antiherpetic Agents
Victor E. Marquez, Juan B. Rodriguez, Marc C. Nicklaus, Joseph J. Barchi, Jr., Maqbool A. Siddiqui (NCI)
U.S. Patent 5,840,728 issued 23 Nov 1998
The compounds of the present invention represent the first examples of carbocyclic dideoxynucleosides that in solution exist locked in a defined N-geometry (C3'-endo) conformation typical of conventional nucleosides. These analogues exhibit increased stability due to the substitution of carbon for oxygen in the ribose ring. The invention includes 4'-6'-cyclopropane fused carbocyclic dideoxynucleosides, 2'-deoxynucleosides and ribonucleosides as well as oligonucleotides derived from these analogues; the preferred embodiment of the invention is carbocyclic-4'-6'-cyclopropane-fused analogues of dideoxypurines, dideoxypyrimidines, deoxypurines, deoxypyrimidines, purine ribonucleosides and pyrimidine ribonucleosides. In addition, oligonucleotides derived from one or more of the nucleosides in combination with the naturally occurring nucleosides are within the scope of the present invention.The second invention discloses a method for the treatment of herpes virus infections by the administration of cyclopropanated carbocyclic 2'-deoxynucleosides to an affected individual. This invention is a method of administration of the compounds described above. The compounds of this invention are particularly efficacious against herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), Epstein-Barr Virus (EBV) and human cytomegalovirus (CMV), although the nucleoside analogues of the invention may be used to treat any condition caused by a herpes virus. Specifically, the N-methanocarba-T (Thymidine) analogue has been shown to exhibit strong activity against HSV-1 and HSV-2, and moderate to strong activity against EBV. Significantly, the anti-HSV activity of the Thymidine analogue is stronger than that of Acyclovir (shown in a plaque reduction assay), a widely used anti-HSV therapeutic. Furthermore, the Thymidine analogue is also non-toxic against stationary cells and is potent against rapidly dividing cells. Dosage amounts for the compounds are similar to those of Acyclovir.Descriptions of these inventions may be found in Rodriguez et al., J. Medicinal Chemistry 37:3389-3399 (1994) and Marquez et al., J. Medicinal Chemistry 39:3739-3747 (1996).
5-Substituted Derivatives of Conformationally Locked Nucleoside Analogues
Victor Marquez, Pamela Russ (NCI)
DHHS Reference No. E-249-00/0, U.S. S/N 60/220,934 filed 26 Jul 2000
This invention relates to 5-substituted derivatives of conformationally locked nucleoside analogues and methods of using these derivatives as antiviral and anticancer agents. The compounds contemplated by the invention are nucleoside analogues where the 5-substituent is a halogen, alkyl, alkene, halovinyl or alkyne group, and the nucleotide base is cytosine or uracil. The analogues are particularly effective in treating viral infections, specifically infections of DNA viruses such as Herpes simplex virus (HSV), Varicella zoster virus (VSV), Epstein Barr virus (EBV), and Cytomegalovirus (CMV) as well as members of the Poxviridae family. The inventors have demonstrated in plaque reduction assays that 5-substituted uracils (bromo, iodo, and bromovinyl) attached to a bicyclo[3.1.0]hexane template are thirty times more potent than acyclovir against HSV-1 and HSV-2.
ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Peter A. Soukas, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7056 ext. 268; fax: 301/402-0220; e-mail: soukasp@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Hepatitis C virus (HCV) is a single stranded RNA virus responsible for the majority of non-A non-B hepatitis. Hepatitis C virus (HCV) has a worldwide distribution and is a major cause of liver cirrhosis and hepatocellular carcinoma in the U.S., Europe, and Japan. For this reason, development of a vaccine against hepatitis C is of great importance. The present inventions claim full-length sequences of HCV, HCV chimeras and HCV derivatives, and methods for using these full-length sequences for a variety of therapeutic and diagnostic applications, including vaccines.
Cloned Genomes of Infectious Hepatitis C Virus and Uses Thereof
Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell (NIAID)
Serial No. 09/014,416 filed 27 Jan 1998, issued as U.S. Patent 6,153,421 on 28 Nov 2000; Serial No. 09/662,454 filed 14 Sep 2000; Canadian Application 2295552; Australian Application 84889/98; European Application 98935702.5
The current invention provides nucleic acid sequences comprising the genomes of infectious hepatitis C viruses (HCV) of genotype 1a and 1b. It covers the use of these sequences, and polypeptides encoded by all or part of the sequences, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Yanagi et al., (1997) Proc. Natl. Acad. Sci., USA 94, 8738-8743 and Yanagi et al. (1998) Virology 244, 151-172.
Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof
Jens Bukh, Masayuki Yanagi, Robert H. Purcell, Suzanne U. Emerson (NIAID)
DHHS Reference No. E-100-99/0, U.S. S/N 60/137,693 filed 04 Jun 1999;
DHHS Reference No. E-100-99/1, PCT/US00/15466 filed 02 Jun 2000
The current invention provides a nucleic acid sequence comprising the genome of infectious hepatitis C viruses (HCV) of genotype 2a. The encoded polyprotein differs from those of the infectious clones of genotypes 1a and 1b (U.S. Patent 6,153,421) by approximately thirty (30) percent. It covers the use of this sequence and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Yanagi et al. (1999), Virology 262, 250-263.
HCV/BVDV Chimeric Genomes and Uses Thereof
Jae-Hwan Nam, Jens Bukh, Robert H. Purcell, Suzanne U. Emerson (NIAID)
DHHS Reference No. E-102-99/0, U.S. S/N 60/137,817 filed 04 June 1999;
DHHS Reference No. E-102-99/1, PCT/US00/15527 filed 02 Jun 2000
The current invention provides nucleic acid sequences comprising chimeric viral genome of hepatitis C Virus (HCV) and bovine viral diarrhea viruses (BVDV). The chimeric viruses are produced by replacing the structural region or a structural gene of an infectious BVDV clone with the corresponding region or gene of an infectious HCV. It covers the use of these sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV.
Infectious cDNA Clone of GB Virus B and Uses Thereof
Jens Bukh, Masayuki Yanagi, Robert H. Purcell, Suzanne U. Emerson (NIAID)
DHHS Reference No. E-173-99/0, U.S. S/N 60/137,694 filed 04 Jun 1999;
DHHS Reference No. E-173-99/1, PCT/US00/15293 filed 02 Jun 2000
The current invention provides nucleic acid sequences comprising the genomes of infectious GB virus B, the most closely related member of the Flaviviridae to hepatitis C virus (HCV). It also covers chimeric GBVB-HCV sequences and polypeptides for use in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Bukh et al. (1999), Virology 262, 470-478.Return to the top of this page
SUMMARY: The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following pending patent. Any license granted shall comply with 35 U.S.C. 209 and 37 CFR part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing ability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; and (6) small business status. Patent application Serial Number 09/747,521 entitled ``Methods for Protection Against Lethal Infection with Bacillus Anthracis'' filed 21 December 2000. The present invention relates to the use selected genes from the pathogen Bacillus anthracis for constructing a plasmid or DNA-based vaccine which can be used to immunize susceptible hosts against the pathogenic effects of B. anthracis infection. Moreover, the invention describes the protective effects of immunization with DNA constructs encoding the Protective Antigen (PA) or the Lethal Factor (LF) and mutants thereof. Most importantly, the invention describes the complete protection of hosts following co-immunization of a host with PA and LF demonstrating a surprising synergistic effect. Lastly, the invention teaches the use of the synergistic effect of PA and/or LF genes for use as a general adjuvant for co-immunization with other DNA or protein based vaccines.
DATES: Applications for an exclusive or partially exclusive license may be submitted at any time from the date of this notice.
ADDRESSES: The Office of Technology Transfer, Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910-7500, telephone (301) 319-7428.
SUMMARY: The inventions listed below are assigned to the United States Government as represented by the Secretary of the Navy and are available for licensing by the Department of the Navy.
ADDRESSES: Requests for copies of the patents cited below should be directed to: Naval Surface Warfare Center Carderock Division, Code 0117, 9500 MacArthur Boulevard, West Bethesda, MD 20817-5700, and must include the patent number.
FOR FURTHER INFORMATION CONTACT: Mr. Dick Bloomquist, Director, Technology Transfer Office, Naval Surface Warfare Center Carderock Division, Code 0117, 9500 MacArthur Boulevard, West Bethesda, MD 20817-5700, telephone (301) 227-4299.
The following patents are available for licensing:
U.S. Patent Number 6,038,995: COMBINED WEDGE-FLAP FOR IMPROVED SHIP
POWERING.//U.S. Patent Number 6,041,728: SHAPE MEMORY ACTUATOR SYSTEM.//
U.S. Patent Number 6,053,664: ELASTOMERIC COMPOSITE BUMPER SYSTEM AND METHOD FOR ABSORBING HIGH ENERGY IMPACT.//
U.S. Patent Number 6,055,924: FOIL ASSISTED MARINE TOWING.//
U.S. Patent Number 6,059,618: VENTILATED OUTBOARD MOTOR-MOUNTED PUMPJET ASSEMBLY.//
U.S. Patent Number 6,069,101: BORON CARBIDE/SILICON CARBIDE CERAMICS.//
U.S. Patent Number 6,075,753: SYSTEM FOR SIMULATION OF UNDERWATER EXPLOSION PRESSURE FIELDS.
//U.S. Patent Number 6,076,480: FUEL STORING WATER BALLAST TANK INTERNALLY STRUCTURED FOR REDUCING RETENTION OF WATER AND OVERBOARD DISCHARGE OF FUEL.//
U.S. Patent Number 6,080,982: EMBEDDED WEAR SENSORS.//
U.S. Patent Number 6,082,436: METHOD OF CENTRIFUGALLY CASTING REINFORCED COMPOSITE ARTICLES.//
U.S. Patent Number 6,097,668: COMPONENT DEPLOYMENT MEANS FOR ICE PENETRATING ACOUSTICS COMMUNICATION RELAY SYSTEM.//
U.S. Patent Number 6,101,963: RUDDER TAB FOR SUPPRESSION OF TIP VORTEX
CAVITATION.//U.S. Patent Number 6,105,716: VENTURI MUFFLER HAVING PLURAL NOZZLES.//
U.S. Patent Number 6,116,328: FABRICATION OF TILE REINFORCED COMPOSITE ARMOR CASTING.//
U.S. Patent Number 6,127,130: MULTIASSAY METHOD OF DETERMINING THE CONCENTRATIONS OF ANTIGENS AND INTERFERANTS.//
U.S. Patent Number 6,138,724: SHIPBOARD PAINT DISPENSING SYSTEM.//
U.S. Patent Number 6,139,648: PRESTRESS IMPOSING TREATMENT OF MAGNETOSTRICTIVE MATERIAL.//
U.S. Patent Number 6,150,974: INFRARED TRANSPARENT RADAR ANTENNA.//
U.S. Patent Number Re. 36,979: SURFACE CONFORMING FLEXIBLE EDDY CURRENT PROBE FOR SCANNING VARYING SURFACE CONTOURS.//
U.S. Patent Number 6,159,060: PROTECTIVE SHROUDING WITH DEBRIS DIVERTING INFLOW VANES FOR PUMP-JET PROPULSION UNIT.//
U.S. Patent Number 6,164,411: SUPPRESSION OF ACOUSTIC CAVITY RESONANCE INDUCED BY FLUID FLOW.//
U.S. Patent Number 6,170,422: ATTACHMENT OF EQUIPMENT TO COMPOSITE SANDWICH CORE STRUCTURES.//
U.S. Patent Number 6,171,159: STEERING AND BACKING SYSTEMS FOR WATERJET CRAFT WITH UNDERWATER DISCHARGE.//
U.S. Patent Number 6,172,510: SYSTEM FOR DETECTION OF FLAWS BY USE OF MICROWAVE RADIATION.//
U.S. Patent Number 6,174,688: MULTIASSAY METHOD FOR DETERMINING THE CONCENTRATIONS OF ANTIGENS AND INTERFERANTS.//
U.S. Patent Number 6,176,943: PROCESSING TREATMENT OF AMORPHOUS MAGNETOSTRICTIVE WIRES.//
U.S. Patent Number 6,182,495: TEST MACHINE FOR SIMULATION OF SHOCK WAVE INDUCED MOTION.//
U.S. Patent Number 6,189,475: PROPELLED CABLE FAIRING.//
U.S. Patent Number 6,192,541: DYNAMIC RAMP INTERFACE SYSTEM.//
U.S. Patent Number 6,196,107: EXPLOSIVE CONTAINMENT DEVICE.//
U.S. Patent Number 6,207,065: INTEGRATED LIQUID DISCHARGE SYSTEM.//
U.S. Patent Number 6,208,268: VEHICLE PRESENCE, SPEED AND LENGTH DETECTING SYSTEM AND ROADWAY INSTALLED DETECTOR THEREFOR.//
U.S. Patent Number 6,213,021: ELECTROMAGNETIC SEA MINE DETONATION SYSTEM.//
U.S. Patent Number 6,227,139: CONTROL TAB ASSISTED LIFT REDUCING SYSTEM FOR UNDERWATER HYDROFOIL SURFACE.//
U.S. Patent Number 6,229,762: ACOUSTIC SENSOR FOR A POINT IN SPACE.//
U.S. Patent Number: 6,235,541: PATTERNING ANTIBODIES ON A SURFACE.
Return to the top of this page
State Science & Technology Institute
5015 Pine Creek Drive
Westerville, OH 43081
Phone: (614) 901-1690
Fax: (614) 901-1696
Email: ssti@ssti.org© 2002 State Science and Technology Institute. All rights reserved.